Erythropoietin-induced deep vein thrombosis in myelodysplastic syndrome

Journal of Association of Physicians of India

Volumn 56, Issue MAR, 2008, Pages 195-196

  Niazy, M N ^a   Neyyarapally, T I ^a   Chattopadhyay, A ^a  

^a AL SABAH HOSPITAL   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

AGED; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; VEIN THROMBOSIS;

AGED, 80 AND OVER; ERYTHROPOIETIN; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; VENOUS THROMBOSIS;

EID: 41649113307     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Melanie SJ. Darbepoietin alfa: a novel erythropoiesis stimulating protein. Ann Pharma 2002;36:1183-87.
2. Dovrish Z, Hadary R, Blickstein D, Shilo L, Ellis MH. Retrospective analysis of the use of inferior vena cava filters in routine hospital practice. Postgrad Med J 2006; 82;150-53.
3. Saba HI. Myelodysplastic syndromes in the elderly: the role of growth factors in management. Leuk Res 1996;20:203-19.
4. Tricot GJ, Lauer RC, Appelbaum FR, et al. Management of the myelodysplastic syndrome. Semin Oncol 1987;14:444-53.
5. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003;59:538-48.
6. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from